(0.82%) 5 124.00 points
(0.15%) 38 345 points
(1.10%) 17 762 points
(0.51%) $84.00
(-2.93%) $1.590
(0.21%) $2 347.50
(0.79%) $27.57
(1.18%) $931.40
(0.07%) $0.932
(0.11%) $10.96
(0.04%) $0.800
(-0.18%) $92.00
Live Chart Being Loaded With Signals
Novo Nordisk A/S is a healthcare company, which engages in the research, development, manufacture, and marketing of pharmaceutical products. The firm is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products...
Stats | |
---|---|
Today's Volume | 26 806.00 |
Average Volume | 51 037.00 |
Market Cap | 406.69B |
EPS | €8.63 ( 2023-06-30 ) |
Last Dividend | €3.00 ( 2023-08-18 ) |
Next Dividend | €0 ( N/A ) |
P/E | 22.91 |
ATR14 | €2.62 (2.86%) |
Volume Correlation
Novo Nordisk A/S Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Novo Nordisk A/S Correlation - Currency/Commodity
Novo Nordisk A/S Financials
Annual | 2022 |
Revenue: | €176.95B |
Gross Profit: | €148.51B (83.92 %) |
EPS: | €24.51 |
Q3 | 2023 |
Revenue: | €58.73B |
Gross Profit: | €49.02B (83.46 %) |
EPS: | €5.02 |
Q2 | 2023 |
Revenue: | €54.30B |
Gross Profit: | €46.44B (85.53 %) |
EPS: | €8.65 |
Q1 | 2023 |
Revenue: | €53.37B |
Gross Profit: | €45.19B (84.67 %) |
EPS: | €8.81 |
Financial Reports:
No articles found.
Novo Nordisk A/S Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
€4.25 (N/A) |
€0 (N/A) |
€8.15 (N/A) |
€0 (N/A) |
€3.00 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | €0.670 | 2002-03-13 |
Last Dividend | €3.00 | 2023-08-18 |
Next Dividend | €0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 30 | -- |
Total Paid Out | €100.58 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 2.88 | -- |
Div. Sustainability Score | 6.14 | |
Div.Growth Potential Score | 4.38 | |
Div. Directional Score | 5.26 | -- |
Year | Amount | Yield |
---|
With a moderate Dividend Sustainability Score (DSS), the company may sustain its dividends, but continuous monitoring is advised for any financial shifts. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
WUW.DE | Ex Dividend Junior | 2023-05-24 | Annually | 0 | 0.00% | |
GDX.DE | Ex Dividend Knight | 2023-10-05 | Quarterly | 0 | 0.00% | |
PFE.DE | Ex Dividend Knight | 2023-07-27 | Quarterly | 0 | 0.00% | |
BIJ.DE | Ex Dividend Knight | 2023-06-21 | Sporadic | 0 | 0.00% | |
HRS.DE | Ex Dividend Knight | 2023-09-01 | Quarterly | 0 | 0.00% | |
SDF.DE | Ex Dividend Junior | 2023-05-11 | Annually | 0 | 0.00% | |
CPIA.F | No Dividend Player | 2023-06-29 | Annually | 0 | 0.00% | |
KSB.DE | Ex Dividend Knight | 2023-05-05 | Annually | 0 | 0.00% | |
2HRA.DE | Ex Dividend Junior | 2023-05-24 | Sporadic | 0 | 0.00% | |
TRVC.DE | Ex Dividend Junior | 2023-08-04 | Quarterly | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.351 | 1.500 | 2.98 | 4.47 | [0 - 0.5] |
returnOnAssetsTTM | 0.251 | 1.200 | 1.635 | 1.962 | [0 - 0.3] |
returnOnEquityTTM | 0.869 | 1.500 | 1.460 | 2.19 | [0.1 - 1] |
payoutRatioTTM | 0.422 | -1.000 | 5.78 | -5.78 | [0 - 1] |
currentRatioTTM | 0.824 | 0.800 | -0.880 | -0.704 | [1 - 3] |
quickRatioTTM | 0.635 | 0.800 | -0.971 | -0.777 | [0.8 - 2.5] |
cashRatioTTM | 0.175 | 1.500 | -0.141 | -0.211 | [0.2 - 2] |
debtRatioTTM | 0.0884 | -1.500 | 8.53 | -10.00 | [0 - 0.6] |
interestCoverageTTM | -18.83 | 1.000 | -8.08 | -8.08 | [3 - 30] |
operatingCashFlowPerShareTTM | 23.78 | 2.00 | 2.07 | 4.15 | [0 - 30] |
freeCashFlowPerShareTTM | 17.38 | 2.00 | 1.308 | 2.62 | [0 - 20] |
debtEquityRatioTTM | 0.285 | -1.500 | 8.86 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.841 | 1.000 | 10.00 | 10.00 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.392 | 1.000 | 4.16 | 4.16 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 4.01 | 1.000 | 10.00 | 10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.715 | 0.800 | 8.57 | 6.85 | [0.5 - 2] |
Total Score | 6.14 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 40.53 | 1.000 | 6.01 | 0 | [1 - 100] |
returnOnEquityTTM | 0.869 | 2.50 | 4.51 | 2.19 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 17.38 | 2.00 | 4.21 | 2.62 | [0 - 30] |
dividendYielPercentageTTM | 0.440 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 23.78 | 2.00 | 2.07 | 4.15 | [0 - 30] |
payoutRatioTTM | 0.422 | 1.500 | 5.78 | -5.78 | [0 - 1] |
pegRatioTTM | 0.142 | 1.500 | -2.38 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.496 | 1.000 | 0.0917 | 0 | [0.1 - 0.5] |
Total Score | 4.38 |
Novo Nordisk A/S
Novo Nordisk A/S is a healthcare company, which engages in the research, development, manufacture, and marketing of pharmaceutical products. The firm is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The firm operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The firm's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The firm's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The firm also offers Saxenda product to treat obesity. The company offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators